— Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 — — Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 — — Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy — — $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to support operations into 1Q27– WESTLAKE VILLAGE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Genelux Corporation...

– Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 – – Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 – – Friedreich’s Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events – – CPVT (SGT-501): Clinical sites activated for Phase 1b ARTEMIS first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic...

— DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 — — Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 — BOSTON, March 19, 2026 (GLOBE NEWSWIRE) — Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. “At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders....

Alpha successfully returned to flight in March, as Firefly enters 2026 with new national security SciTec contracts.“Stairway to Seven” launching from Firefly’s Space Launch Complex 2 at Vandenberg Space Force Base in California on March 11, 2026. CEDAR PARK, Texas, March 19, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today issued financial results for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a transformative year in Firefly’s history, as we more than doubled our annual revenue while executing across multiple launch, spacecraft, and ground programs and strengthening our portfolio of space exploration and national security space capabilities,” said Jason Kim, CEO of Firefly Aerospace. “Our laser...

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — Gemini Space Station, Inc. (“Gemini”) (NASDAQ: GEMI) today reported its fourth quarter and full year 2025 financial results in a shareholder letter and earnings presentation which can be found on its Investor Relations website at https://investors.gemini.com. Management will host a conference call at 8:30 am ET tomorrow, March 20, to discuss the results. The event will be webcast live via our Investor Relations website or via this link. Following the call, a replay and transcript will also be available at https://investors.gemini.com. Channels for Disclosure of Information As a reminder, we announce material information to the public through filings with the Securities and Exchange Commission (SEC), the investor relations page on our website (investors.gemini.com), the blog on our website...

Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 million Launched DESMODA™, the first and only FDA-approved desmopressin oral solution Licensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earnings Company expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30% Management to hold conference call today at 4:30pm ETDEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results...

Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP Net Loss Improved by $25.5 million; Adjusted EBITDA Improved by $8.5 million $46.1 million of Cash and Marketable Securities and no debt Board Authorizes $10 Million Share Repurchase Program 2026 Outlook: Revenue of $162 million to $168 million and Breakeven Adjusted EBITDA(1) DENVER, March 19, 2026 (GLOBE NEWSWIRE) — GrowGeneration Corp. (NASDAQ: GRWG), (“GrowGeneration,” “GrowGen” or the “Company”), one of the nation’s largest suppliers of specialty products for controlled environment agriculture (CEA), commercial cultivation, and garden centers, today announced financial results for the fourth quarter and full year ended December 31,...

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) – Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – Reported Positive Phase 2 Data of SLS009 in Relapsed/Refractory (r/r) AML at ASH 2025 – – $71.8 Million in Cash and Cash Equivalents as of December 31, 2025; Additional $42.6 Million in Proceeds Received in Q1 2026 to Date Through Warrant Exercises – NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2025, and provided...

CULVER CITY, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights ARK Franchise Updates:ARK: Survival Evolved (“ASE”):Units sold were approximately 579,248 for the fourth quarter 2025 During the fourth quarter of 2025, average daily active users (“DAU”) was 105,468 and peak DAU was 137,404ARK: Survival Ascended (“ASA”):Units sold were approximately 691,872 for the fourth quarter 2025 During the fourth quarter of 2025, average DAU was 91,123 and peak DAU was 147,572 Launched ARK Lost Colony DLC Launched ‘ARK x Teenage Mutant Ninja...

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – – Phase 2 initiation for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus, anticipated by end of 2026 – SOUTH SAN FRANCISCO, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2025, and recent highlights. “2025 was a pivotal year for the Company, and we anticipate another strong year ahead,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “Compelling...